Here are five things to know:
1. The company anticipates clearance and expanded geographic sales footprint to further accelerate the silicon nitride adoption for use in biomedical applications.
2. Amedica plans to obtain a Brazilian clearance for the second generation Valeo II silicon nitride interbody fusion devices and instrumentation set in the future.
3. Amedica’s material is the only alternative to PEEK and titanium systems cleared in Brazil.
4. The biomaterial offers anti-infective properties and a favorable environment for bone growth.
5. Amedica expects to see incremental revenue growth as early as this quarter after the clearance for distribution in Brazil.
More articles on orthopedic devices:
SeaSpine launches Ventura NanoMetalene spine device: 5 key points
K2M, InVivo Therapeutics, Zimmer & more—19 key notes
Global sports medicine market to reach $53.6B by 2022: 6 key trends
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
